key: cord-0917174-ur99293s
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Myocarditis following mRNA-Based COVID-19 Vaccines: Correspondence
date: 2022-02-14
journal: Cardiology
DOI: 10.1159/000522588
sha: c2187c600a7b07ce51f310da823fe5bafda1495b
doc_id: 917174
cord_uid: ur99293s

n/a.

Dear Editor, We would like to share ideas on the publication "Incidence, clinical presentation and management of myocarditis following mRNA-based Covid-19 vaccines: A brief report [1] ." Saeed et al. [1] concluded that "myocarditis following mRNA-based Covid-19 vaccines is rare, more frequently affects younger men <30 years and … outweighs the risk of post-vaccination myocarditis.

[C1]." The COVID-19 vaccine, we agree, has the potential to induce negative effects. A heart issue may occur in the patient, which may or may not be related to the COVID-19 vaccination. Because there is no information about the patient's immunological status before to immunization, it is impossible to make a firm conclusion. Several possible underlying pathomechanisms including abnormal immune response and viscosity charge are proposed as an underlying cause of a cardiac problem. It is also likely that a vaccination recipient might experience a medical issue at the same time. For example, among CO-VID-19 vaccine recipients, dengue fever is a possible concurrent medical condition that might cause myocarditis [2] . Finally, due to the mild nature of the heart condition, there may be underreported cases around the world. Therefore, the discussed incidence by Saeed et al. [1] should be lower than the exact incidence. Despite the lack of a precise management recommendation, we believe that patient followup is beneficial.

Not applicable.

The authors have no conflicts of interest to report.

No funding was received for this letter.

R.M. contributed to 50% of the following: 1a substantial contributions to study conception and design; 1b. substantial contributions to acquisition of data; 1c. substantial contributions to analysis and interpretation of data; 2. drafting the article or revising it critically for important intellectual content; and 3. final approval of the version of the article to be published. V.W. contributed to 50% of the following: 1a substantial contributions to study conception and design; 1b. substantial contributions to acquisition of data; 1c. substantial contributions to analysis and interpretation of data; 2. drafting the article or revising it critically for important intellectual content; and 3. final approval of the version of the article to be published.

Incidence, clinical presentation and management of myocarditis following mRNA-based Covid-19 vaccines: a brief report

Dengue after COVID-19 vaccination: possible and might be missed